Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
1999 1
2001 1
2003 1
2007 3
2008 2
2009 1
2010 1
2011 3
2012 4
2013 4
2014 8
2015 6
2016 7
2017 13
2018 9
2019 12
2020 20
2021 17
2022 18
2023 6
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

130 results

Results by year

Filters applied: . Clear all
Page 1
Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action.
Willsmore ZN, Coumbe BGT, Crescioli S, Reci S, Gupta A, Harris RJ, Chenoweth A, Chauhan J, Bax HJ, McCraw A, Cheung A, Osborn G, Hoffmann RM, Nakamura M, Laddach R, Geh JLC, MacKenzie-Ross A, Healy C, Tsoka S, Spicer JF, Josephs DH, Papa S, Lacy KE, Karagiannis SN. Willsmore ZN, et al. Among authors: karagiannis sn. Eur J Immunol. 2021 Mar;51(3):544-556. doi: 10.1002/eji.202048747. Epub 2021 Feb 23. Eur J Immunol. 2021. PMID: 33450785 Free article. Review.
Myosin II Reactivation and Cytoskeletal Remodeling as a Hallmark and a Vulnerability in Melanoma Therapy Resistance.
Orgaz JL, Crosas-Molist E, Sadok A, Perdrix-Rosell A, Maiques O, Rodriguez-Hernandez I, Monger J, Mele S, Georgouli M, Bridgeman V, Karagiannis P, Lee R, Pandya P, Boehme L, Wallberg F, Tape C, Karagiannis SN, Malanchi I, Sanz-Moreno V. Orgaz JL, et al. Among authors: karagiannis sn. Cancer Cell. 2020 Jan 13;37(1):85-103.e9. doi: 10.1016/j.ccell.2019.12.003. Cancer Cell. 2020. PMID: 31935375 Free PMC article.
Regional Activation of Myosin II in Cancer Cells Drives Tumor Progression via a Secretory Cross-Talk with the Immune Microenvironment.
Georgouli M, Herraiz C, Crosas-Molist E, Fanshawe B, Maiques O, Perdrix A, Pandya P, Rodriguez-Hernandez I, Ilieva KM, Cantelli G, Karagiannis P, Mele S, Lam H, Josephs DH, Matias-Guiu X, Marti RM, Nestle FO, Orgaz JL, Malanchi I, Fruhwirth GO, Karagiannis SN, Sanz-Moreno V. Georgouli M, et al. Among authors: karagiannis sn. Cell. 2019 Feb 7;176(4):757-774.e23. doi: 10.1016/j.cell.2018.12.038. Epub 2019 Jan 31. Cell. 2019. PMID: 30712866 Free PMC article.
Utilizing Immunocytokines for Cancer Therapy.
Runbeck E, Crescioli S, Karagiannis SN, Papa S. Runbeck E, et al. Among authors: karagiannis sn. Antibodies (Basel). 2021 Mar 9;10(1):10. doi: 10.3390/antib10010010. Antibodies (Basel). 2021. PMID: 33803078 Free PMC article. Review.
B cell profiles, antibody repertoire and reactivity reveal dysregulated responses with autoimmune features in melanoma.
Crescioli S, Correa I, Ng J, Willsmore ZN, Laddach R, Chenoweth A, Chauhan J, Di Meo A, Stewart A, Kalliolia E, Alberts E, Adams R, Harris RJ, Mele S, Pellizzari G, Black ABM, Bax HJ, Cheung A, Nakamura M, Hoffmann RM, Terranova-Barberio M, Ali N, Batruch I, Soosaipillai A, Prassas I, Ulndreaj A, Chatanaka MK, Nuamah R, Kannambath S, Dhami P, Geh JLC, MacKenzie Ross AD, Healy C, Grigoriadis A, Kipling D, Karagiannis P, Dunn-Walters DK, Diamandis EP, Tsoka S, Spicer J, Lacy KE, Fraternali F, Karagiannis SN. Crescioli S, et al. Among authors: karagiannis sn. Nat Commun. 2023 Jun 8;14(1):3378. doi: 10.1038/s41467-023-39042-y. Nat Commun. 2023. PMID: 37291228 Free PMC article.
Anti-cancer pro-inflammatory effects of an IgE antibody targeting the melanoma-associated antigen chondroitin sulfate proteoglycan 4.
Chauhan J, Grandits M, Palhares LCGF, Mele S, Nakamura M, López-Abente J, Crescioli S, Laddach R, Romero-Clavijo P, Cheung A, Stavraka C, Chenoweth AM, Sow HS, Chiaruttini G, Gilbert AE, Dodev T, Koers A, Pellizzari G, Ilieva KM, Man F, Ali N, Hobbs C, Lombardi S, Lionarons DA, Gould HJ, Beavil AJ, Geh JLC, MacKenzie Ross AD, Healy C, Calonje E, Downward J, Nestle FO, Tsoka S, Josephs DH, Blower PJ, Karagiannis P, Lacy KE, Spicer J, Karagiannis SN, Bax HJ. Chauhan J, et al. Among authors: karagiannis sn. Nat Commun. 2023 Apr 25;14(1):2192. doi: 10.1038/s41467-023-37811-3. Nat Commun. 2023. PMID: 37185332 Free PMC article.
Mechanisms of checkpoint inhibition-induced adverse events.
Urwyler P, Earnshaw I, Bermudez M, Perucha E, Wu W, Ryan S, Mcdonald L, Karagiannis SN, Taams LS, Powell N, Cope A, Papa S. Urwyler P, et al. Among authors: karagiannis sn. Clin Exp Immunol. 2020 May;200(2):141-154. doi: 10.1111/cei.13421. Epub 2020 Feb 21. Clin Exp Immunol. 2020. PMID: 31989585 Free PMC article. Review.
Special Issue "Antibody Engineering for Cancer Immunotherapy".
Crescioli S, White AL, Karagiannis SN. Crescioli S, et al. Among authors: karagiannis sn. Antibodies (Basel). 2022 Apr 15;11(2):29. doi: 10.3390/antib11020029. Antibodies (Basel). 2022. PMID: 35466282 Free PMC article.
Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trial.
Spicer J, Basu B, Montes A, Banerji U, Kristeleit R, Miller R, Veal GJ, Corrigan CJ, Till SJ, Figini M, Canevari S, Barton C, Jones P, Mellor S, Carroll S, Selkirk C, Nintos G, Kwatra V, Funingana IG, Doherty G, Gould HJ, Pellizzari G, Nakamura M, Ilieva KM, Khiabany A, Stavraka C, Chauhan J, Gillett C, Pinder S, Bax HJ, Josephs DH, Karagiannis SN. Spicer J, et al. Among authors: karagiannis sn. Nat Commun. 2023 Jul 25;14(1):4180. doi: 10.1038/s41467-023-39679-9. Nat Commun. 2023. PMID: 37491373 Free PMC article. Clinical Trial.
130 results